Semax is a synthetic heptapeptide engineered from a fragment of a natural human hormone, and its status depends almost entirely on geography: an approved prescription medicine inside Russia, an unapproved research chemical nearly everywhere else. That split is the single most important thing to grasp about it, because the evidence and oversight that back the Russian drug do not travel with the powder sold internationally. What follows documents where the molecule came from, how it is built, and why the same substance carries two very different levels of accountability.
Semax is a Russian-developed synthetic heptapeptide derived from the ACTH(4-10) hormone fragment, registered as a medicine in Russia but sold in the United States and Europe only as an unapproved research chemical without verified safety, purity, or efficacy.
At the chemical level Semax is a heptapeptide, a chain of seven amino acids in the fixed order Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues reproduce the 4-through-7 portion of the natural ACTH(4-10) fragment, while the final Pro-Gly-Pro tail is a synthetic addition, and that tail is the defining engineering trick: prolines resist the enzymes that normally chop peptides apart, so bracketing the active core lets the molecule survive long enough to reach the brain instead of degrading within minutes.
Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, a molecular weight near 813 daltons, whose synthetic Pro-Gly-Pro tail resists enzymatic breakdown that destroys the raw ACTH fragment within minutes.
Semax traces back to adrenocorticotropic hormone, or ACTH, a pituitary hormone whose main job is signaling the adrenal glands to make cortisol. Research showed that one internal stretch, the ACTH(4-10) segment, carries effects on attention, learning, and memory that are separate from the hormone's role in the stress axis, and that neuroactive fragment became the starting scaffold. The record describes a deliberate choice: keep the cognitive and neuroprotective signal while dropping the parts of ACTH that drive cortisol.
Semax is derived from the ACTH(4-10) fragment of adrenocorticotropic hormone but retains only residues 4 through 7 plus a Pro-Gly-Pro tail, so it does not act as a hormone or meaningfully stimulate cortisol release.
Semax is a Russian invention, developed in the Soviet Union and Russia rather than in the Western pharmaceutical industry. The core work is credited to scientists at the Institute of Molecular Genetics of the Russian Academy of Sciences, working with researchers at the P.K. Anokhin Institute of Normal Physiology and associated academic groups, which places its origin in state-backed academic and physiological research rather than a private company's commercial pipeline.
Semax was developed by scientists at the Institute of Molecular Genetics of the Russian Academy of Sciences with the P.K. Anokhin Institute of Normal Physiology, in the Soviet and Russian state-backed academic tradition of peptide neuropharmacology.
The development of Semax spans the late Soviet and early post-Soviet years, growing out of earlier Soviet study of ACTH fragments and their effects on the brain. The stabilized heptapeptide emerged from that program by the late 1980s, moved through Russian medical evaluation during the 1990s, and was registered as an approved medicine in Russia in that decade. Its later appearance abroad came by a different route entirely, circulating in the 2010s through the online research chemical and nootropic community rather than being exported as an approved drug.
Semax's stabilized heptapeptide emerged by the late 1980s, was registered as an approved medicine in Russia during the 1990s, and only reached international markets in the 2010s as an unregulated research chemical.
Semax was engineered as a therapeutic aimed at the brain and circulation, not as a general enhancement supplement. The original design goal was to capture the neuroprotective and cognition-supporting effects of the ACTH(4-10) fragment and turn them into a usable drug, which meant solving the fragment's fatal weakness: the natural piece is destroyed within minutes, so the Pro-Gly-Pro tail was added to give the molecule enough stability to act. The gap between that clinical purpose and the off-label nootropic reputation abroad is one of the most important distinctions to understand, because the evidence behind the approved indications does not automatically extend to enhancement claims.
Semax was designed as a neuroprotective and cerebrovascular therapeutic, approved in Russia for indications such as ischemic stroke recovery and circulation-related cognitive impairment, not as the general focus aid its unregulated international market promotes.
The regulatory status of Semax splits sharply along geographic lines, and that divide is central to any honest description. In Russia and a small number of nearby countries such as Ukraine it is a legitimately registered prescription medicine that has passed national approval; in the United States it has no such standing, is not FDA-approved for any use, and is not a recognized dietary ingredient. The research chemical and not-for-human-consumption labeling is not a formality: it signals that the product has not been tested or manufactured under the standards that apply to real medicines, and that no regulator has verified its identity, purity, dosage, or safety.
| Jurisdiction | Status | What it means |
|---|---|---|
| Russia (and e.g. Ukraine) | Registered prescription medicine | Passed national approval, used in clinical settings |
| United States | Not FDA-approved; sold as research chemical | Labeled not for human consumption, no verified safety or efficacy |
| European Union | Not approved as a medicine | Same unapproved status across most of Europe |
Semax is a registered prescription medicine only in Russia and a few neighboring countries; it holds no FDA or EU approval and is sold in the United States and Europe as an unapproved research chemical with no verified identity, purity, dosage, or safety.
Semax reaches users in two very different presentations that track its two-track status. The Russian medical product is a low-concentration nasal drop or spray solution, a ready-to-use liquid dosed into the nose so the peptide reaches the nervous system directly without being destroyed in the digestive tract. The unregulated version sold internationally is most often a lyophilized (freeze-dried) powder in a small sealed vial, kept dry because peptides degrade in water, and the most important difference is not the form but what stands behind it: the nasal medicine carries a verified concentration, while the powder carries no guarantee of amount, purity, or even identity.
Semax is supplied as a pharmaceutical-grade nasal solution at a verified concentration in Russia and as a freeze-dried powder in a sealed vial internationally, the latter carrying no guarantee of amount, purity, or identity.
Semax is routinely mentioned alongside several other peptides, but treating them as interchangeable is a mistake rooted in the marketplace rather than the biology. Its closest relative, Selank, comes from the same Russian research lineage and sells through the same channels, yet descends from a different parent molecule (the immune peptide tuftsin) and targets anxiety rather than cognition and stroke recovery. It also gets grouped with unrelated compounds such as BPC-157, which shares nothing with Semax in origin, structure, or intended action, and the practical danger of blurring these lines is that dosing habits and safety assumptions get carried from one thinly studied peptide to another.
| Peptide | Parent origin | Primary reported focus |
|---|---|---|
| Semax | ACTH hormone fragment | Cognition, stroke recovery, neuroprotection |
| Selank | Immune peptide tuftsin | Anxiety |
| BPC-157 | Stomach protein fragment | Tissue repair |
Semax is engineered from the ACTH hormone system and focused on cognition and stroke recovery, distinct from Selank, which derives from tuftsin and targets anxiety, and from the unrelated tissue-repair peptide BPC-157.
Educational use only. This article describes what the published scientific and clinical literature reports about Semax. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
